LAB GmbH Has New Major Equity Holder
LAB GmbH of Germany, which says it is one of the leading contract research organizations for human pharmacology - with subsidiaries in Europe, the USA and Japan, claims to be approaching the millennium with new strength.
It reveals that Hofkammer des Hauses Wurttemberg, a German investment group which inter alia manages the shareholdings of the former king of Wurttemberg, has acquired a majority equity position in LAB for some $2.5 million, and will provide the capital required for its planned expansion. As a result, LAB expects to strengthen its market position in clinical research, will develop new and innovative galenic capabilities and will implement new technologies at its bioanalytical and information technology divisions.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze